Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sawai USA
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Sawai USA is the U.S. generic pharmaceutical business of Sawai Group, commercializing a broad portfolio of oral solid and other small-molecule generics, primarily for cardiovascular, metabolic, oncology, and other chronic conditions, leveraging manufacturing and R&D capabilities of the Sawai group.[1][2][4][6]
- Therapeutic areas
- EndocrinologyCardiovascularOtherOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Upsher-Smith (use of its U.S. manufacturing base and commercial network following Sawai’s acquisition of Upsher-Smith’s generics business)[1]
Beyond the preview
Go deeper on Sawai USA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sawai USA.